Discovery of 6-[(3 S,4 S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor

Barbara Czako, Yuting Sun, Timothy McAfoos, Jason B. Cross, Paul G. Leonard, Jason P. Burke, Christopher L. Carroll, Ningping Feng, Angela L. Harris, Yongying Jiang, Zhijun Kang, Jeffrey J. Kovacs, Pijus Mandal, Brooke A. Meyers, Faika Mseeh, Connor A. Parker, Simon S. Yu, Christopher C. Williams, Qi Wu, Maria Emilia Di FrancescoGiulio Draetta, Timothy Heffernan, Joseph R. Marszalek, Nancy E. Kohl, Philip Jones

Research output: Contribution to journalArticlepeer-review

Abstract

Src homology 2 (SH2) domain-containing phosphatase 2 (SHP2) plays a role in receptor tyrosine kinase (RTK), neurofibromin-1 (NF-1), and Kirsten rat sarcoma virus (KRAS) mutant-driven cancers, as well as in RTK-mediated resistance, making the identification of small-molecule therapeutics that interfere with its function of high interest. Our quest to identify potent, orally bioavailable, and safe SHP2 inhibitors led to the discovery of a promising series of pyrazolopyrimidinones that displayed excellent potency but had a suboptimal in vivo pharmacokinetic (PK) profile. Hypothesis-driven scaffold optimization led us to a series of pyrazolopyrazines with excellent PK properties across species but a narrow human Ether-à-go-go-Related Gene (hERG) window. Subsequent optimization of properties led to the discovery of the pyrimidinone series, in which multiple members possessed excellent potency, optimal in vivo PK across species, and no off-target activities including no hERG liability up to 100 μM. Importantly, compound 30 (IACS-15414) potently suppressed the mitogen-activated protein kinase (MAPK) pathway signaling and tumor growth in RTK-activated and KRASmut xenograft models in vivo.

Original languageEnglish (US)
Pages (from-to)15141-15169
Number of pages29
JournalJournal of Medicinal Chemistry
Volume64
Issue number20
DOIs
StatePublished - Oct 28 2021

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Discovery of 6-[(3 S,4 S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor'. Together they form a unique fingerprint.

Cite this